.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
UBS
Mallinckrodt
Argus Health
Chubb
QuintilesIMS
McKesson
Novartis
AstraZeneca
Dow

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,747,897

« Back to Dashboard

Which drugs does patent 8,747,897 protect, and when does it expire?


Patent 8,747,897 protects ORENITRAM and is included in one NDA. There have been two Paragraph IV challenges on Orenitram.

This patent has sixteen patent family members in eight countries.

Summary for Patent: 8,747,897

Title:Osmotic drug delivery system
Abstract: An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in a elementary osmotic pump delivery system and at least one release enhancing agent.
Inventor(s): Kidane; Argaw (Montgomery Village, MD), Bhatt; Padmanabh P. (Rockville, MD)
Assignee: Supernus Pharmaceuticals, Inc. (Rockville, MD)
Application Number:11/412,100
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Delivery; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
United TherapORENITRAMtreprostinil diolamineTABLET, EXTENDED RELEASE;ORAL203496-001Dec 20, 2013RXYesNo► Subscribe► SubscribeY► Subscribe
United TherapORENITRAMtreprostinil diolamineTABLET, EXTENDED RELEASE;ORAL203496-002Dec 20, 2013RXYesNo► Subscribe► SubscribeY► Subscribe
United TherapORENITRAMtreprostinil diolamineTABLET, EXTENDED RELEASE;ORAL203496-003Dec 20, 2013RXYesNo► Subscribe► SubscribeY► Subscribe
United TherapORENITRAMtreprostinil diolamineTABLET, EXTENDED RELEASE;ORAL203496-004Dec 20, 2013RXYesYes► Subscribe► SubscribeY► Subscribe
United TherapORENITRAMtreprostinil diolamineTABLET, EXTENDED RELEASE;ORAL203496-005Oct 7, 2016RXYesNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,747,897

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,393,203Osmotic drug delivery system► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,747,897

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria532520► Subscribe
Canada2649243► Subscribe
China101466384► Subscribe
European Patent Office2010189► Subscribe
European Patent Office2368556► Subscribe
Spain2377387► Subscribe
Spain2399200► Subscribe
Japan2009535337► Subscribe
Japan2013139468► Subscribe
Japan2016026155► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Mallinckrodt
Merck
Citi
AstraZeneca
US Department of Justice
Argus Health
McKinsey
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot